To evaluate target inhibition, phosphorylated ERK, total ERK, and cyclin D1 protein levels were evaluated by Western blot analysis on available serial tumor biopsy specimens collected at baseline, day 3 (on treatment), and between days 11 and 14 (off treatment). The gene discussed is CCND1; the disease is neoplasm.